BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22075664)

  • 1. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
    Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
    Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
    Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
    Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
    Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
    Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
    Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
    Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
    Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
    Yamaguchi T; Takii Y; Maruyama S
    Surg Today; 2014 Aug; 44(8):1529-35. PubMed ID: 23975589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.
    Takahashi R; Sakamoto K; Sugimoto K; Motegi S; Tsukamoto R; Ichikawa R; Okazawa Y; Aoki J; Ishiyama S; Takahashi M; Kojima Y; Okuzawa A; Tomiki Y; Matsuoka J
    Dis Markers; 2019; 2019():2721876. PubMed ID: 31929839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of preoperative serum anti-p53 antibodies in gastric cancer.
    Nakajima K; Suzuki T; Shimada H; Hayashi H; Takeda A; Ochiai T
    Tumour Biol; 1999; 20(3):147-52. PubMed ID: 10213922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
    Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
    Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
    Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
    Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
    Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
    Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
    Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
    Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
    Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
    Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
    Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
    Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
    Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
    Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
    Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
    Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.